Sharemaestro Newsreel

Harrow Schedules Aug. 11 Call to Discuss Second-Quarter Results

Harrow (Nasdaq: HROW) will report its second-quarter 2026 financial results after the market close on Monday, August 10, 2026. The company will also host a conference call and live webcast to discuss the results and provide a business update at 8:00 a.m. Eastern Time …

HUTCHMED (China) Ltd (HCM) Cash Flow

The article provides a detailed cash flow statement for HUTCHMED (China) Ltd (HCM), presenting both annual and quarterly data. It covers operating, investing, and financing cash flows, along with free cash flow, to help evaluate the company's financial health. The data includes year-over-year percentage …

Amneal Pharmaceuticals, Inc. Class A Revenue Breakdown – FWB:2DT

Amneal Pharmaceuticals, Inc. Class A (FWB:2DT) generated 2.57 billion EUR last year, with its Affordable Medicines segment being the top performer contributing 1.49 billion EUR. The primary revenue sources by region were the United States, India, and Ireland. The company's total revenue saw a …

Supernus Pharmaceuticals Inc (SUPN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Supernus Pharmaceuticals Inc (SUPN) focusing on its dividend and stock split history. It notes that the company has not distributed dividends totaling 0.00 USD over the past five years and contains no data on past dividend payments or …

Weekly Recap: Guggenheim hikes NBIX price target and Siddhanti named CBO

Guggenheim has reiterated a Buy rating on Neurocrine Biosciences (NBIX) and increased its price target to $200. Additionally, Neurocrine Biosciences has appointed Samir Siddhanti as its new Chief Business Officer, tasked with driving growth, business development, and corporate strategy, aiming to maximize the value …

BioAge Labs, Inc. $BIOA Shares Sold by Orbimed Advisors LLC

Orbimed Advisors LLC reduced its stake in BioAge Labs (NASDAQ:BIOA) by 10% in the first quarter, selling 79,090 shares and retaining 711,811 shares valued at approximately $12.45 million. Despite this, other institutional investors like Geode Capital Management, Marshall Wace, and Mirae Asset Global ETFs …

ISS recommends shareholders vote for all Aurora Cannabis resolutions

Institutional Shareholder Services Inc. (ISS) has advised shareholders of Aurora Cannabis Inc. (NASDAQ: ACB) to approve all proposed resolutions at the company's upcoming Annual General Meeting on August 7, 2026. The resolutions include fixing the number of directors, electing directors, appointing an auditor, and …

Aurora Cannabis (NASDAQ: ACB) wins ISS support for 2026 shareholder vote

Institutional Shareholder Services (ISS) has recommended that Aurora Cannabis shareholders vote FOR all resolutions at its upcoming 2026 Annual General Meeting. The virtual AGM is scheduled for August 7, 2026, with a proxy voting deadline of August 5, 2026. Aurora's CEO, Miguel Martin, welcomed …

Biofrontera Inc (BFRI) Cash Flow

This article provides a detailed cash flow statement for Biofrontera Inc (BFRI), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures in millions of USD, along with year-over-year percentage changes, and includes FAQs explaining key cash flow concepts …

Rice Hall James & Associates LLC Acquires Shares of 251,066 Xeris Biopharma Holdings, Inc. $XERS

Rice Hall James & Associates LLC recently acquired 251,066 shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) worth approximately $1.46 million, contributing to institutional and hedge fund ownership of 42.75% of the company. Analysts maintain a "Moderate Buy" rating with a consensus target price of …

Regencell Bioscience Holdings Ltd (RGC) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Regencell Bioscience Holdings Ltd (RGC). It details the institutional shareholding and shareholder activity, listing various firms and their stake changes. The data indicates significant institutional interest and varying portfolio adjustments among these investors.

Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring a 7.17% Potential Upside in the Healthcare Sector

Lantheus Holdings Inc. (LNTH), a healthcare company specializing in diagnostic and therapeutic products, shows a potential upside of 7.17% according to analyst ratings. The company maintains a market capitalization of $6.82 billion, a forward P/E of 16.64, and strong financial health with $421.7 million …

Curium in Talks to Acquire Lantheus For $7 Billion

Curium is reportedly in discussions to acquire Lantheus Holdings, Inc. for $7 billion. This potential acquisition follows recent news of Lantheus weighing a sale after Curium's initial offer. Lantheus specializes in radiopharmaceuticals for diagnostics and treatment in areas like oncology, neurology, and cardiology.

Amphastar Pharmaceuticals Inc (AMPH) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Amphastar Pharmaceuticals Inc (AMPH), listing major shareholders such as Applied Physics & Chemistry Laboratories, Inc., BlackRock Institutional Trust Company, N.A., and key individual investors. It also provides a breakdown of shareholder types, institutional holdings over several quarters, …

Rice Hall James & Associates LLC Increases Position in Amphastar Pharmaceuticals, Inc. $AMPH

Rice Hall James & Associates LLC increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 54.6% in the first quarter, now holding 187,348 shares valued at $3.67 million. Despite institutional ownership accounting for 65.09% of the company, Amphastar Pharmaceuticals missed first-quarter earnings and revenue estimates …

Octagon Capital Advisors LP Has $30.57 Million Stock Position in BioAge Labs, Inc. $BIOA

Octagon Capital Advisors LP has increased its holdings in BioAge Labs, Inc. by 9.4%, now owning 1.748 million shares valued at $30.57 million. BioAge Labs, a clinical-stage biotechnology company, reported a smaller-than-expected quarterly loss of $0.52 per share on $2.77 million in revenue, though …

Regencell Bioscience Holdings Ltd (RGC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Regencell Bioscience Holdings Ltd (RGC), detailing various technical indicators and moving averages to assess its current stock performance. It includes a summary of buy, sell, and neutral signals from indicators like MACD, RSI, and STOCH, as well …

TRLV|Trulieve Cannabis Subordinate Voting Ord Shs|Price:9.650|Chg%:+0.035

This article provides a detailed profile of Trulieve Cannabis Corp. (TRLV), a vertically integrated cannabis company. It covers the company's background, business scope, financial data, and market performance, highlighting its operations in three regional hubs and its various cannabis brands. The profile also lists …

Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Lifecore Biomedical Inc (LFCR)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past 5 years, indicating no recent dividend payouts. The page also presents current stock data for LFCR.

Gabelli Funds LLC Has $9.60 Million Stock Position in Perrigo Company plc $PRGO

Gabelli Funds LLC increased its stake in Perrigo Company plc (NYSE:PRGO) by 29.8% to $9.60 million in the first quarter, now holding 893,359 shares. Despite reporting quarterly EPS of $0.43 which beat estimates, Perrigo's revenue declined 7.2% year over year, and the company posted …

Supernus Pharmaceuticals Inc (SUPN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article provides a detailed revenue breakdown for Supernus Pharmaceuticals Inc (SUPN), presenting its financial performance by business segments and regional contributions. The data covers various fiscal years and quarters, highlighting key product sales such as Qelbree, GOCOVRI, APOKYN, and Trokendi XR, along with …

Sei Investments Co. Has $35.62 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

Sei Investments Co. increased its stake in Teva Pharmaceutical Industries Ltd. by 22.5% in the first quarter, bringing its total holding to $35.62 million. While institutional investors collectively own 54.05% of Teva and analysts maintain a "Moderate Buy" rating, company insiders have sold approximately …

Castleark Management LLC Raises Stock Position in Elanco Animal Health Incorporated $ELAN

Castleark Management LLC significantly increased its stake in Elanco Animal Health (NYSE: ELAN) by 931.4% in the first quarter, holding 355,950 shares valued at $8.5 million. This aligns with broader institutional ownership, with 97.48% of the company owned by hedge funds and other large …

Emergent BioSolutions Inc (EBS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Emergent BioSolutions Inc (EBS), outlining its major institutional holders, investor types, and activity. It highlights that BlackRock, Dimensional Fund Advisors, and State Street are among the top shareholders. The report also provides a historical overview of institutional …

Pacira BioSciences Enrolls First Patient in Mid-stage Trial After Manufacturing Milestone

Pacira BioSciences has enrolled its first patient in a mid-stage clinical trial for PCRX-201, a gene therapy aimed at treating osteoarthritis. This milestone follows the successful transition of PCRX-201 to a scalable commercial manufacturing process, underscoring the company's progress in advancing its non-opioid pain …

Biofrontera Inc (BFRI) Income Statement

This article presents the quarterly and annual income statements for Biofrontera Inc (BFRI), providing detailed financial figures such as total revenue, cost of revenue, operating expenses, and net income stretching back to Q1 2020. It allows users to analyze the company's financial performance and …

DERM|Journey Medical Corp|Price:6.360|Chg%:+0.170

This article provides a detailed profile of Journey Medical Corporation (DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological products. It covers the company's background, business scope, key products like Qbrexza and Accutane, financial data including market capitalization, and lists key executives along with …

Rockwell Medical Inc (RMTI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Rockwell Medical Inc (RMTI), highlighting its performance by business segments and geographical regions. For the specified fiscal year, the company generated revenue primarily from Concentrate Products and Drug Products. The regional analysis indicates significant revenue contributions …

Eton Pharmaceuticals Inc (ETON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Eton Pharmaceuticals Inc (ETON), focusing on its business segments and regional contributions. It notes that relevant data for FY2025 and its quarters, as well as FY2024, have not yet been disclosed by the company. However, it does …

Anika Therapeutics (ANIK) Proxy filing Summary

Anika Therapeutics (ANIK) recently filed a proxy summary detailing proposed changes to its 2017 Omnibus Incentive Plan, particularly Proposal 4, which faces dilution concerns despite board approval. The plan continues to use a fungible design for executive compensation, assigning higher cost to full-value awards. …

Journey Medical Corp (DERM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Citius Oncology Inc (CTOR) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits. The piece presents …

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Pacira BioSciences announced the successful transition of its investigational gene therapy, PCRX-201, to a scalable commercial manufacturing process, enabling the enrollment of the first patient in Part B of the Phase 2 ASCEND study. This milestone supports the company's "5x30 growth strategy" and reduces …

SIGA Technologies Inc Financials

This article provides a detailed financial overview of SIGA Technologies Inc. It presents the company's financial summary, including income statement, balance sheet, and cash flow statement data, both quarterly and annually. Key financial indicators like EPS, revenue, net profit, net margin, and gross margin …

SIGA Technologies Inc (SIGA) Cash Flow

This article provides a detailed cash flow statement for SIGA Technologies Inc (SIGA), outlining quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as operating cash flow, net income from continuing operations, capital expenditures, and free cash flow. …

Perrigo Company PLC (PRGO) Cash Flow

This article provides a detailed overview of Perrigo Company PLC's cash flow statement, including operating, investing, and financing activities. It presents both annual and quarterly financial data for various cash flow components, helping users assess the company's financial soundness. The article also includes a …